Johnson & Johnson (JNJ)

No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.

By failing to settle like Purdue Pharma, JNJ is taking a risky gamble that could open itself up to many more state court battles and penalties.

Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.

I am not focused on today's price movement of the stock but the pattern from the end of 2017.

Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.

3M, Caterpillar and Johnson & Johnson all face headwinds with a strong dollar.

Traders could go long on the eye-care company on strength above $62 risking below $59 with a $72 price target.

Stranger things have happened, but with NFLX's subscriber miss, the stock just became hard money, joining the likes of Johnson & Johnson and CSX Corp.

It's a stock picker's market as action in individual stocks is better than on the indexes.

It is still a surprisingly sedate market, despite indexes sitting close to all-time highs, earnings season, possible interest-rate cuts and endless speculation about China trade.

For those trading the FANG or FAANG names, and especially Facebook, Tuesday sets up as a day bearing exceptional levels of headline risk.

The bulls will say this is healthy consolidation that will set up another leg higher, while the bears will say this is an indication of indecision and is a prelude to a rollover.

Here are my five rules for handling earnings season.

The stock has been bouncing off the 200-day moving average line.

Investors have shown an increasing interest in ESG Investing. These top investment vehicles emphasize strong business operations and social responsibilities.

I want you to remember Eli Lilly and Johnson & Johnson the next time you are about to dump a stock because of some bits of bad news.

When traders are flailing and investors are drowning, examples work best to illustrate what happens before a bottom is reached.

Let's take a serious look at the charts and indicators.

Dividend stock investors should look to have at least some exposure to this sector.

As usual, the stocks that bounce back first are the tech stocks with little Chinese exposure and the consumer packaged goods that just demonstrated good numbers.

Especially when healthcare CEOs discus political issues with analysts and reporters.

Recapping a big day of earnings for both names.

When Netflix reports earnings tonight, what will likely matter above all else for now will be subscriber growth.

The biggest challenge is even if JNJ beats and raises guidance, the overhang of litigation could still prevent overzealous trading.

Healthcare giants Johnson & Johnson and Pfizer offer a tough choice for dividend investors seeking the best returns.

There's been enough news with the lawsuits around this name to get the emotion back into the stock. Emotion often leads to volatility.